New study tracks Octreotide's Real-World impact on acromegaly over two years
NCT ID NCT07583563
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study follows 200 people with acromegaly who are using octreotide subcutaneous depot, a medication that helps control hormone levels. Researchers will monitor safety and effectiveness for up to two years in everyday clinical practice, not a controlled lab setting. The goal is to see how well the drug works in real life and what side effects may occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- octreotide subcutaneous depot
- What this could lead to
- If successful, this study could confirm that octreotide SC depot is a safe and effective long-term treatment option for managing acromegaly in everyday practice.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new drug but gathers real-world data on an existing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
RECRUITINGMagdeburg, 39110, Germany
-
Medicover Neuroendokrinologie MVZ
NOT_YET_RECRUITINGMünchen, 81667, Germany
-
St James's University Hospital - Leeds Teaching Hospitals NHS Trust
NOT_YET_RECRUITINGLeeds, LS9 7TF, United Kingdom
-
Universitaetsklinikum Aachen
NOT_YET_RECRUITINGAachen, 52074, Germany
-
Universitaetsklinikum Leipzig
RECRUITINGLeipzig, 04103, Germany
-
Universitätsklinikum Würzburg
RECRUITINGWürzburg, 97080, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Growth-Hormone blocker stay safe in everyday use? a korean study investigates
- Which intubation method works best for acromegaly patients?
- New octreotide pill faces off against current capsule in healthy volunteer study
- New software could improve acromegaly care
- New drug MAR002 aims to tame acromegaly in early trial
- Scientists hunt for hidden genes behind pituitary tumors